| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-08-30 | Genentech, a member of Roche Group (USA - CA - Switzerland) Syndax Pharmaceuticals (USA - MA) | entinostat and atezolizumab | triple-negative breast cancer | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2015-08-30 | STEMCELL Technologies (Canada) iPS Academia Japan (Japan) | technologies for induced pluripotent stem cell (iPS cell) research | licensing |
Technology - Services | Licensing agreement | |
| 2015-08-30 | BMS (USA - NY) QIMR Berghofer Medical Research Institute (Australia) | therapeutic antibodies against an undisclosed immuno-oncology target | R&D licensing |
Cancer - Oncology | Licensing agreement | |
| 2015-08-27 | Valneva (France- Austria) The Chemo-Sero-Therapeutic Research Institute (Kaketsuken) (Japan) | EB66® cell line | undisclosed | licensing |
undisclosed | Licensing agreement |
| 2015-08-27 | Valneva (France- Austria) Fatro (Italy) | EB66® cell line | undisclosed | licensing |
Veterinary medicine | Licensing agreement |
| 2015-08-27 | QB3@953 (USA - CA) GSK (UK) | collaboration |
Collaboration agreement | |||
| 2015-08-26 | Corgenix Medical Corporation (USA - CO) Fio Corporation (Canada) | rapid test for the Ebola virus | Ebola fever | collaboration |
Infectious diseases | Collaboration agreement |
| 2015-08-26 | Takeda Pharmaceutical (Japan) Nanotherapeutics (USA - FL) | Vero cell technology platform | pandemic and seasonal influenza | licensing commercialisation |
Infectious diseases | Licensing agreement |
| 2015-08-26 | Immatics Biotechnologies (Germany) | Immatics US | establishment of a new subsidiary in the US |
Cancer - Oncology | Establishment of a new subsidiary in the US | |
| 2015-08-26 | Novo Nordisk (Denmark) | type 1 diabetes, type 2 diabetes | construction of a production plant |
Metabolic diseases | Construction of a production plant | |
| 2015-08-26 | Alvogen (USA _ NJ) Pfizer (USA - NY) | clindamycin injection, acetylcysteine inhalation solution, voriconazole injection, melphalan injection | product acquisition |
Product acquisition | ||
| 2015-08-26 | Redhill Biopharma (Israel) Recipharm (Sweden) | RHB-105 (amoxicillin, rifabutin and omeprazole) | Helictobacter pylori infection | production manufacturing |
Infectious diseases | Production agreement |
| 2015-08-26 | Agilent Technologies (USA - CA) Weill Cornell Medical College (USA - NY) | amyotrophic lateral sclerosis | R&D |
Neurodegenerative diseases - Rare diseases | R&D agreement | |
| 2015-08-25 | MorphoSys (Germany) Immatics Biotechnologies (Germany) | novel antibody-based therapeutics against multiple proprietary cancer antigens recognized by T cells | solid tumors, hematological cancers | development |
Cancer - Oncology | Development agreement |
| 2015-08-25 | Acucela (USA - MA) | nomination |
Ophtalmological diseases | Nomination | ||
| 2015-08-25 | Shire (UK - USA) Sanquin Blood Supply (The Netherlands) | Cinryze® (C1 esterase inhibitor ) | hereditary angioedema (HAE) | production manufacturing |
Rare diseases - Genetic diseases | Production agreement |
| 2015-08-24 | AstraZeneca (UK) | nomination |
Nomination | |||
| 2015-08-24 | Halozyme Therapeutics (USA - CA) | nomination |
Nomination | |||
| 2015-08-24 | Amag Pharmaceuticals (USA - MA) | nomination |
Nomination | |||
| 2015-08-20 | Cellectis (France) ModiQuest Research (The Netherlands) | monoclonal antibodies against Cellectis’ targets | collaboration development |
Cancer - Oncology | Collaboration agreement |
